Lorlatinib Shows Promise in ALK Driven Neuroblastoma
Lorlatinib demonstrated encouraging activity in patients with anaplastic lymphoma kinase (ALK) driven neuroblastoma, with particularly strong responses observed in those harbouring ALK hotspot mutations, according to new preliminary findings from a cohort of 25 patients.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Updates in Diagnosis, Management, and Treatment of Neuroblastoma
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study